Treatment for Seronegative Autoimmune Autonomic Ganglionopathy
For seronegative AAG (now termed seronegative autoimmune autonomic neuropathy or SAAN), intravenous corticosteroids are the first-line immunotherapy, as this condition responds poorly to antibody-targeted treatments like IVIG or plasma exchange that work in seropositive disease. 1
Key Distinction: Seronegative vs Seropositive Disease
Seronegative AAG represents a distinct clinical entity from seropositive AAG, requiring fundamentally different treatment approaches 1. The critical differences are:
- Pathophysiology: Predominant sympathetic (rather than cholinergic) failure
- Clinical features: Prominent sensory symptoms and pain (often severe), absence of premature pupillary redilation seen in seropositive AAG
- Treatment response: Responds to steroids, NOT to antibody-targeted therapies 1
Treatment Algorithm
First-Line Therapy: Intravenous Corticosteroids
Intravenous methylprednisolone is the primary immunomodulatory treatment 2, 1. Three of six patients in the defining seronegative cohort responded to IV steroids, whereas IVIG, plasma exchange, and rituximab were ineffective 1.
- Start with high-dose IV methylprednisolone (typical pulse dosing: 500-1000 mg daily for 3-5 days)
- Transition to oral prednisone with gradual taper based on clinical response
- Monitor for improvement in orthostatic hypotension, gastrointestinal symptoms, and sensory complaints
Second-Line Options: Plasma Exchange/Apheresis
If steroids alone are insufficient, add plasma exchange or apheresis 2. One documented case showed good response to combined IV methylprednisolone and apheresis after initial treatment failure 2.
Refractory Cases: Rituximab
Rituximab may be considered for steroid-refractory seronegative disease, though evidence is limited 3. In a literature review, rituximab showed positive effects in only 2 of 4 SAAN cases (compared to 5 of 5 seropositive AAG cases), suggesting lower efficacy in seronegative disease 3.
- Dosing: 1 g IV once weekly for 4 weeks, or standard lymphoma protocol
- Consider only after failure of steroids and plasma exchange
- May be used in combination with other immunotherapies 3
Critical Pitfalls to Avoid
Do not start with IVIG or plasma exchange alone - these antibody-targeted therapies are ineffective in seronegative disease when used as monotherapy 1
Do not assume treatment response will mirror seropositive AAG - the immunopathology differs fundamentally
Do not overlook pain management - sensory symptoms and neuropathic pain are prominent in seronegative disease and require specific attention with gabapentinoids or other neuropathic pain medications 1
Symptomatic Management
While pursuing immunotherapy, aggressive symptomatic treatment is essential:
- Orthostatic hypotension: Midodrine, fludrocortisone, atomoxetine, compression garments, increased salt/fluid intake
- Gastrointestinal dysmotility: Prokinetic agents, dietary modifications, laxatives for constipation
- Urinary retention: Intermittent catheterization if needed
- Neuropathic pain: Gabapentin, pregabalin, or duloxetine
Monitoring Response
Track improvement using:
- Orthostatic vital signs (lying and standing blood pressure)
- Autonomic symptom questionnaires (COMPASS-31)
- Quantitative autonomic testing if available
- Patient-reported functional status and pain scores
The response to treatment in seronegative AAG is generally less robust than in seropositive disease, and residual autonomic impairment commonly persists despite immunotherapy 1.